#GENINCODE #GENI $GENI As of February 2026, GENinCode (AIM: GENI) is indeed drawing attention as a potential takeover candidate. This speculation is driven by a stark contrast between its low market valuation and its high-value intellectual property in the cardiovascular predictive genetics sector. Factors Driving Takeover Interest Depressed Valuation: Following a deeply discounted fundraising in early 2026 at 1p per share, the company's market capitalisation fell to approximately £8.10 million. Analysts view this as a significant "deep discount" compared to consensus price targets ranging from 7.5p to 11.5p. Strategic US Assets: GENinCode's primary value driver is its CARDIO inCode-Score test, which targets a US market estimated at $10.5 billion. The company is currently addressing final FDA "deficiencies" for its De Novo application, with data submission expected in Q1 2026. Proprietary Technology: Beyond its clinical tests, the company owns SITAB®, a cloud-based AI bioinformatics portal that integrates genetic and clinical data for healthcare providers. Acquisition Rationale: Market analysts suggest the company is a high-reward candidate for larger medical device or diagnostics corporations looking to rapidly enter the polygenic risk score (PRS) market. Current Financial Status Fundraising: In early 2026, the company raised approximately £4.7 million to extend its cash runway and support US regulatory goals. Consensus Rating:professional analysts maintain a "Strong Buy" consensus. Next Steps: Would you like to track the Q1 2026 FDA submission progress or see a comparison of GENinCode's valuation against its primary competitors in the genetics sector?

#GENinCode (AIM: #GENI) is currently viewed by some market analysts and investors as a potential takeover target due to its depressed valuation and strategic assets in the predictive genetics sector. Current Market Context Deep Discounting: As of February 2026, the company recently completed a fundraising of approximately £4.7 million at a significant discount to provide a cash runway for its U.S. regulatory goals. Valuation vs. Potential: Despite its low market capitalisation—noted at approximately £8.10 million in late February 2026—analysts maintain a consensus "Strong Buy" with target prices as high as 7.50p to 11.5p, representing a massive premium over current trading levels. Regulatory Catalysts: The company is currently addressing FDA "deficiencies" for its CARDIO inCode-Score test, with a final data submission expected in Q1 2026. Success here would unlock a U.S. market estimated at $10.5 billion. The company is currently classified as an advanced clinical pipeline and recently secured funding make it a high-reward candidate for acquisition by a larger medical device or diagnostics corporation looking to enter the polygenic risk score (PRS) market.

5-year, 7-figure collaboration for @GenIncode Based on recent chatter on investor forums (as of February 16, 2026), there are reports of a potential 5-year, 7-figure collaboration for #GENinCode Plc (#GENI) expected to be announced, with some sources indicating a joint venture (JV) involving a major Spanish genetics company linked to a 'Sergio Olivero'. Company Involved: GENinCode Plc (#AIM: $GENI), an Oxford-based company focusing on cardiovascular disease (CVD) predictive genetics. The Rumor: Social media posts on platforms like X, Reddit, and Telegram suggest a 7-figure [p/a], 5-year collaboration is slated for announcement, possibly next week. Key Individuals/Entities: The collaboration is reportedly a joint venture with a major Spanish genetics firm that has connections to someone called "Sergio Olivero".

$GENI Retail investors remain sceptical about prospects at #GENinCode, with only 13% take-up of retail offer. Taken together with Placing, gross cash raised was £4.07m. Aiming to use this to generate sales traction. investors.genincode.com/archive/2025/1…

#GENI #GENINCODE One to keep any eye on. NHS order bidstats.uk/tenders/2024/W…

#dnaworldday celebrates the discovery of the #dna double helix structure. Thanks to this discovery, #GenIncode tests now provide information about inherited conditions, disease diagnosis and improved risk assessment in #cardiovasculardisease. #cardioincode #lipidincode

#GENI #genincode FDA news is due anytime now. The article below highlights how generic testing can help identify those at risk of cardiovascular disease. #tbl0002" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl… cardio incode test from genenicode is regarded as “first in class”!

#GENI #Genincode 177m shares. MC £8.41m 52week H:25p, L4.75 (current) Cash ~£6m Estimated rev 2023 £1.5-2m and growing. •Significant and growing demand for US Early Access Program with over 40 institutions now onboarding for LIPID inCode® for the diagnosis of familial 1/3

#UK: Mid-Market Update ✦#GENinCode (medical software) falls more than -1% as the company raises £4.1 million at £0.05 per share #StockMarket #FTSE100 4/5

#GENI #Genincode rns files.q4europe.com/news-pdf/34273…

#GENI #genincode the RNS this morning does seem remarkable for a small UK company and I guess the US will want stock when their markets open 😎